Requests for Proposals

President’s Malaria Initiative (PMI) Insights Program

The U.S. President’s Malaria Initiative (PMI) Insights for Malaria (Insights) project partners with malaria-endemic countries to ensure the most effective and efficient use of resources to fight malaria and save lives.

PMI, through the PMI Insights project, is providing technical support to WHO and Gavi for the creation of a country-driven malaria vaccine research agenda consisting of a prioritized list of research questions to inform investments in malaria vaccine implementation research. The research agenda will focus on key evidence gaps and information needs to ensure effective and efficient first-generation malaria vaccine roll-out and scale-up.

To support the implementation of this activity, PATH seeks an interested institution to co-lead the development of the malaria vaccine research agenda in collaboration with the PMI Insights project team.

Proposals due: March 13, 2023

Instructions

Fact-finding questions and responses

This is an opportunity to apply for funding to advance research applications for development of new HIV prevention approaches. Applicants from a wide range of US, Kenyan, South African, and Zimbabwean institutions are invited to apply to this request for applications sponsored by the Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence (MATRIX) consortium and United States Agency for International Development.

We are seeking innovative research applications for the development of new HIV prevention drug and strategies, multipurpose prevention technologies (MPTs), and technologies that enable HIV prevention strategy development and have the potential to strengthen capacity in targeted countries.

Established researchers, research consortia, students, postdoctoral fellows, and new investigators establishing laboratories and/or seeking tenure from the United States, Kenya, South Africa, and Zimbabwe are encouraged to apply.

Proposed research must be driven by milestones, go/no-go criteria, and timelines, and must target development of HIV prevention for one or more of the following populations: adolescent girls and young women, pregnant and breastfeeding women, and female sex workers.

Applications are limited to projects with costs of US$150,000 and a duration of 18 months. PATH, a member of the MATRIX consortium, will oversee the application submission and award processes using an oversight structure that draws from US- and Africa-based administrators.

Instructions on how to apply and templates for the application are below:

• Instructions
• Template for main application
• Template for budget narrative
• Template for detailed budget
• Financial risk assessment questionnaire
• Answers to fact-finding questions
• Budget requirements update (issued on March 2, 2023)
• Fact-finding questions cost sharing update

Key dates

• Release of request for applications: December 1, 2022 (8:00 a.m. Pacific time)
• Letter of intent due: February 1, 2023 (8:00 a.m. Pacific time) Closed
• Fact-finding questions due: February 1, 2023 (8:00 a.m. Pacific time) Closed
• Applicants provided responses to fact-finding questions: February 15, 2023 (8:00 a.m. Pacific time) Closed
• Applications due: March 10, 2023 (8:00 a.m. Pacific time)
• Applicants notified of decision: May 10, 2023 (8:00 a.m. Pacific time)
• Estimated project start date: June 1, 2023

Note that MATRIX reserves the right to modify this schedule as needed. Parties who express interest will be notified by email of any changes.

This request for applications expires on March 11, 2023.

HIV self-testing Africa (STAR) is a Unitaid-funded initiative that currently operates in 13 countries. It aims to catalyze the global market for HIV self-testing, generate evidence, and create an enabling environment for scale-up. Through the HIV STAR consortium, PATH will conduct implementation research to assess different hepatitis C virus (HCV) self-testing delivery models in two HIV STAR countries—India and Vietnam, which have a high HCV disease burden, and diagnostic gaps among key populations and people living with HIV. To support the research study in Vietnam, we are looking for a vendor to provide HCV treatment products, namely Sofosbuvir 400mg and Daclatasvir 60mg (Daclatasvir dihydrochloride). Quantity and detailed requirements are linked below.

RFQ requirements and instructions

If you have the listed products available, please send us a quotation by March 30, 2023. Quotations received after this date are ineligible. For further information, please contact:

Finance/administration:

Name: Mr. Tran Minh Dung

Email: dtran@path.org

Technical/program team:

Name: Mr. Do Tuan Kim

Email: kdo@path.org

Procurement associate:

Name: Ms. Nguyen Thuc Hang

Email: htnguyen@path.org